SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (23403)7/21/1998 4:10:00 PM
From: Phil Cressman  Read Replies (2) | Respond to of 32384
 
Damn frustrating that every time LGND's price nears $13 it's back down to just over $12 again. It's as bad as watching resource stock prices and perhaps one just has to wait until the whole biopharma sector gets hot once again.



To: jayhawk969 who wrote (23403)7/24/1998 6:07:00 PM
From: jayhawk969  Read Replies (1) | Respond to of 32384
 
On Topic

The posted release has interesting implications when tested against Ligand. Size, and staying power are two critical issues. The comments also lead one to believe that industry rationalization will pick up steam. More Seragen type acquisitions can be expected along with mergers of various sizes. Everything many of us have questioned and criticized may well be strengths.

biz.yahoo.com

J.D.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News